$EARS has catalysts coming in 2017 Q4 and 2018 Q1 and Q4:
Phase 3 AM-111 HEALOS - for Acute inner ear hearing loss. Completion of enrollment announced June 5, 2017. Data due 4Q 2017.
Phase 1 AM-125, an intranasal formulation of betahistine for the treatment of Meniere's disease and other vestibular disorders. Goal is to start Phase 1 in Q4 2017.
Phase 3 AM-101 Keyzilen TACTT3 - for Acute inner ear tinnitus. Enrollment resumption announced January 26, 2017 with top-line data 1Q 2018.
Phase 3 AM-111 ASSENT - for Acute inner ear hearing loss. Data due 2H 2018.
$EARS needs some good data on HEALOS! They are clearly hedging with AM-125 in the same quarter. The good news is they are a penny stock bio with THREE Phase 3 trials underway. High risk, high reward.
Know What You Own. My posts should not be construed as investment advice.
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM